Junshi and Revitope team up for TEAC molecules through development, license, and equity
Clients Shanghai Junshi Biosciences Co., Ltd.
Jones Day represented Shanghai Junshi Biosciences Co., Ltd. in a research collaboration and license agreement with Revitope Oncology Inc. and its subsidiary to collaborate in the research and development of T-cell engaging cancer immunotherapies that utilize Junshi's antibody technology platform with Revitope's proprietary dual-antigen targeting technology platform. Junshi will designate up to 5 T-cell immunotherapeutic molecules. Revitope will receive a combination of development and commercialization milestones and tiered royalties on net sales. In addition, Junshi committed an equity investment into Revitope for up to 9.99% of its shares on an as-converted basis.